362 results on '"Allen-Auerbach, Martin"'
Search Results
2. FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysis
- Author
-
Maliha, Peter George, Hotta, Masatoshi, Farolfi, Andrea, Grogan, Tristan, Alano, Rejah, Limon, Andrea, Lam, Ethan, Carlucci, Giuseppe, Bahri, Shadfar, Salavati, Ali, Benz, Matthias, Silverman, Daniel, Gupta, Pawan, Quon, Andrew, Allen-Auerbach, Martin, Czernin, Johannes, and Calais, Jeremie
- Published
- 2024
- Full Text
- View/download PDF
3. Visual and whole-body quantitative analyses of 68 Ga-DOTATATE PET/CT for prognosis of outcome after PRRT with 177Lu-DOTATATE
- Author
-
Hotta, Masatoshi, Sonni, Ida, Thin, Pan, Nguyen, Kathleen, Gardner, Linda, Ciuca, Liliana, Hayrapetian, Artineh, Lewis, Meredith, Lubin, David, and Allen-Auerbach, Martin
- Published
- 2024
- Full Text
- View/download PDF
4. Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression
- Author
-
Ruchalski, Kathleen, Kim, Hyun J, Douek, Michael, Raman, Steven, Patel, Maitraya, Sai, Victor, Gutierrez, Antonio, Levine, Benjamin, Fischer, Cheryce, Allen-Auerbach, Martin, Gupta, Pawan, Coy, Heidi, Villegas, Bianca, Brown, Matthew, and Goldin, Jonathan
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Urologic Diseases ,Prostate Cancer ,Cancer ,Castration ,Disease Progression ,Humans ,Male ,Prostatic Neoplasms ,Castration-Resistant ,Retrospective Studies ,Tomography ,X-Ray Computed ,Treatment Outcome ,RECIST ,Disease progression ,Prostate cancer ,Visceral metastases ,Nuclear Medicine & Medical Imaging ,Clinical sciences ,Oncology and carcinogenesis - Abstract
BackgroundTo evaluate the anatomic site(s) of initial disease progression in patients with castration resistant metastatic prostate cancer (mCRPC) in the presence or absence of pre-treatment visceral metastases while on systemic therapy.MethodsThis is a retrospective cohort study of mCRPC patients who have baseline and at least one follow up bone scan and CT chest, abdomen and pelvis (CAP). Disease progression was determined by RECIST and/or ≥ 30% increase in automated bone scan lesion area score. Kaplan-Meier plot was used to estimate the median progression free survival and log-rank tests were used to compare anatomic sites.ResultsOf 203 patients, 61 (30%) had pre-treatment visceral metastases. Patients with baseline visceral disease were 1.5 times more likely to develop disease progression (HR = 1.53; 95% CI, 1.03-2.26). Disease progression was a result of worsening bone scan disease (42% (16/38)) versus visceral (32% (12/38)) or lymph node disease (3% (1/38)) by CT or a combination thereof (23% (9/38)). Median time to progression (TTP) did not differ by anatomic location of initial progression (p = 0.86). Development of new lesions occurred in 50% of those visceral patients with soft tissue only progression and was associated with a significantly longer TTP (3.1 months (2.8-4.3 months) than those with worsening of pre-existing lesions (1.8 months (1.6-2.7 months); p = 0.04.ConclusionsPatients with pre-treatment visceral metastases in mCRPC are more likely to experience disease progression of bone disease with the initial anatomic site of progression similar to those without baseline visceral involvement.
- Published
- 2022
5. Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial
- Author
-
Sonni, Ida, Felker, Ely R, Lenis, Andrew T, Sisk, Anthony E, Bahri, Shadfar, Allen-Auerbach, Martin, Armstrong, Wesley R, Suvannarerg, Voraparee, Tubtawee, Teeravut, Grogan, Tristan, Elashoff, David, Eiber, Matthias, Raman, Steven S, Czernin, Johannes, Reiter, Robert E, and Calais, Jeremie
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Prostate Cancer ,Aging ,Biomedical Imaging ,Urologic Diseases ,Cancer ,Clinical Research ,Prevention ,Bioengineering ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Gallium Isotopes ,Gallium Radioisotopes ,Humans ,Male ,Multiparametric Magnetic Resonance Imaging ,Positron Emission Tomography Computed Tomography ,Prospective Studies ,Prostatic Neoplasms ,Reproducibility of Results ,PSMA PET/CT ,prostate cancer ,mpMRI ,staging ,T staging ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
The role of prostate-specific membrane antigen (PSMA)-targeted PET in comparison to multiparametric MRI (mpMRI) in the evaluation of intraprostatic cancer foci is not well defined. The aim of our study was to compare the diagnostic performance of 68Ga-PSMA-11 PET/CT (PSMA PET/CT), mpMRI, and PSMA PET/CT + mpMRI using 3 independent masked readers for each modality and with histopathology as the gold standard in the detection, intraprostatic localization, and determination of local extension of primary prostate cancer. Methods: Patients with intermediate- or high-risk prostate cancer who underwent PSMA PET/CT as part of a prospective trial (NCT03368547) and mpMRI before radical prostatectomy were included. Each imaging modality was interpreted by 3 independent readers who were unaware of the other modality result. A central majority rule was applied (2:1). Pathologic examination of whole-mount slices was used as the gold standard. Imaging scans and whole-mount slices were interpreted using the same standardized approach on a segment level and a lesion level. A "neighboring" approach was used to define imaging-pathology correlation for the detection of individual prostate cancer foci. Accuracy in determining the location, extraprostatic extension (EPE), and seminal vesicle invasion (SVI) of prostate cancer foci was assessed using receiver-operating-characteristic curve analysis. Interreader agreement was calculated using intraclass correlation coefficient analysis. Results: The final analysis included 74 patients (14 [19%] with intermediate risk and 60 [81%] with high risk). The cancer detection rate (lesion-based analysis) was 85%, 83%, and 87% for PSMA PET/CT, mpMRI, and PSMA PET/CT + mpMRI, respectively. The change in AUC was statistically significant between PSMA PET/CT + mpMRI and the 2 imaging modalities alone for delineation of tumor localization (segment-based analysis) (P < 0.001) but not between PSMA PET/CT and mpMRI (P = 0.093). mpMRI outperformed PSMA PET/CT in detecting EPE (P = 0.002) and SVI (P = 0.001). In the segment-level analysis, intraclass correlation coefficient analysis showed moderate reliability among PSMA PET/CT and mpMRI readers using a 5-point Likert scale (range, 0.53-0.64). In the evaluation of T staging, poor reliability was found among PSMA PET/CT readers and poor to moderate reliability was found for mpMRI readers. Conclusion: PSMA PET/CT and mpMRI have similar accuracy in the detection and intraprostatic localization of prostate cancer foci. mpMRI performs better in identifying EPE and SVI. For the T-staging evaluation of intermediate to high-risk prostate cancer, mpMRI should still be considered the imaging modality of reference. Whenever available, PSMA PET/MRI or the coregistration or fusion of PSMA PET/CT and mpMRI (PSMA PET/CT + mpMRI) should be used as it improves tumor extent delineation.
- Published
- 2022
6. Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips
- Author
-
Sun, Na, Yang, Yingying, Miao, Hui, Redublo, Peter, Liu, Hongtao, Liu, Wenfei, Huang, Yen-Wen, Teng, Pai-Chi, Zhang, Ceng, Zhang, Ryan Y, Smalley, Matthew, Yang, Peng, Chou, Shih-Jie, Huai, Kevin, Zhang, Zhicheng, Lee, Yi-Te, Wang, Jasmine J, Wang, Jing, Liang, Icy Y, Zhang, Tiffany X, Zhang, Dongyun, Liang, Li, Weiss, Paul S, Posadas, Edwin M, Donahue, Timothy, Hecht, J Randolph, Allen-Auerbach, Martin S, Bergsland, Emily K, Hope, Thomas A, Pei, Renjun, Zhu, Yazhen, Tseng, Hsian-Rong, and Heaney, Anthony P
- Subjects
Analytical Chemistry ,Chemical Sciences ,Engineering ,Biomedical Engineering ,Nanotechnology ,Health Disparities ,Cancer ,Clinical Research ,Minority Health ,Neurosciences ,Biomarkers ,Tumor ,Biosensing Techniques ,Humans ,Neoplasm Metastasis ,Neoplastic Cells ,Circulating ,Neuroendocrine Tumors ,Circulating tumor cells ,Circulating tumor cell clusters ,Nanostructured substrates ,Neuroendocrine tumor ,Peptide receptor radionuclide therapy ,Bioinformatics ,Analytical chemistry ,Biomedical engineering - Abstract
Circulating tumor cell (CTC) clusters are present in cancer patients with severe metastasis, resulting in poor clinical outcomes. However, CTC clusters have not been studied as extensively as single CTCs, and the clinical utility of CTC clusters remains largely unknown. In this study, we aim sought to explore the feasibility of NanoVelcro Chips to simultaneously detect both single CTCs and CTC clusters with negligible perturbation to their intrinsic properties in neuroendocrine tumors (NETs). We discovered frequent CTC clusters in patients with advanced NETs and examined their potential roles, together with single NET CTCs, as novel biomarkers of patient response following peptide receptor radionuclide therapy (PRRT). We observed dynamic changes in both total NET CTCs and NET CTC cluster counts in NET patients undergoing PRRT which correlated with clinical outcome. These preliminary findings suggest that CTC clusters, along with single CTCs, offer a potential non-invasive option to monitor the treatment response in NET patients undergoing PRRT.
- Published
- 2022
7. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
- Author
-
Calais, Jeremie, Czernin, Johannes, Thin, Pan, Gartmann, Jeannine, Nguyen, Kathleen, Armstrong, Wesley R, Allen-Auerbach, Martin, Quon, Andrew, Bahri, Shadfar, Gupta, Pawan, Gardner, Linda, Dahlbom, Magnus, He, Beilei, Esfandiari, Rouzbeh, Ranganathan, David, Herrmann, Ken, Eiber, Matthias, Fendler, Wolfgang P, and Delpassand, Ebrahim
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Patient Safety ,Prostate Cancer ,Clinical Trials and Supportive Activities ,Clinical Research ,Cancer ,Urologic Diseases ,6.1 Pharmaceuticals ,Humans ,Male ,Heterocyclic Compounds ,1-Ring ,Lutetium ,Aged ,Dipeptides ,Middle Aged ,Prospective Studies ,Prostatic Neoplasms ,Castration-Resistant ,Glutamate Carboxypeptidase II ,Safety ,Ligands ,Molecular Targeted Therapy ,Antigens ,Surface ,Aged ,80 and over ,Radiopharmaceuticals ,Prostate-Specific Antigen ,metastatic castration-resistant prostate cancer ,radionuclide therapy ,molecular radiotherapy ,prostate-specific membrane antigen ,Lu-177 ,RESIST-PC ,prospective randomized phase 2 trial ,theranostics ,safety ,177Lu ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
The purpose of this analysis was to report the safety evaluation of 177Lu-PSMA-617 derived from the cohort of 64 patients exposed to 177Lu-PSMA-617 in the RESIST-PC trial NCT03042312 Methods: RESIST-PC was a prospective multicenter phase 2 trial. Patients with progressive metastatic castration-resistant prostate cancer after ≥ 1 novel androgen-axis drug, either chemotherapy naïve or postchemotherapy, with sufficient bone marrow reserve, normal kidney function, sufficient PSMA expression by PSMA PET, and no PSMA-negative soft-tissue lesions were eligible. Patients were randomized (1:1) into 2 activity groups (6.0 or 7.4 GBq per cycle) and received up to 4 cycles every 8 wk. The primary safety endpoint was assessed by collecting and grading adverse events using the Common Terminology Criteria for Adverse Events. Patients were followed until disease progression, death, serious or intolerable adverse events, study termination by sponsor, patient withdrawal, lost to follow-up, or 24 mo after the first cycle. Results: The study was closed at enrollment of 71 of 200 planned patients because of sponsorship transfer. A total of 64 (90.1%) patients received at least 1 cycle of 177Lu-PSMA-617: 28 (36%) in arm 1 (6.0 GBq) and 41 (64%) in arm 2 (7.4 GBq). There were 10 (43.5%), 19 (46.5%), and 29 (45.3%) patients who completed 4 cycles of 177Lu-PSMA-617 in the 6.0-GBq arm, 7.4-GBq arm, and overall, respectively. The most common treatment-emergent adverse events (TEAEs) of any grade in the 6.0-GBq arm, the 7.4-GBq arm and overall, were dry mouth (47.8%; 63.4%; 57.8%, respectively), fatigue (56.5%; 51.2%; 53.1%, respectively), nausea (52.2%; 43.9%; 46.9%, respectively), and diarrhea (13.0%; 31.7%; 25.0%, respectively). Frequencies of all other TEAEs were comparable among the 2 groups (within 10% difference). Serious possibly drug-related TEAEs were reported for 5 (7.8%) patients overall (none were considered as probably or definitely related to treatment): 1 subdural hematoma grade 4, 1 anemia grade 3, 1 thrombocytopenia grade 4, 1 gastrointestinal hemorrhage grade 3, and 1 acute kidney injury grade 3. There were no clinically significant changes in vital signs in electrocardiograms in the 2 treatment groups. No trend to creatinine increase or increasing frequency of shifts from normal to abnormal over time for any hematologic parameter was noted. Conclusion:177Lu-PSMA-617 was safe and well-tolerated at 6.0 and 7.4 GBq per cycle given at 8-wk intervals with side effects easily managed with standard medical support. With established safety, further clinical trials applying individualized dosimetry and testing different 177Lu-PSMA-617 administration schemes (activity levels, time intervals) are needed to optimize tumor dose delivery and treatment efficacy.
- Published
- 2021
8. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
- Author
-
Calais, Jeremie, Gafita, Andrei, Eiber, Matthias, Armstrong, Wesley R, Gartmann, Jeannine, Thin, Pan, Nguyen, Kathleen, Lok, Vincent, Gosa, Laura, Grogan, Tristan, Esfandiari, Rouzbeh, Allen-Auerbach, Martin, Quon, Andrew, Bahri, Shadfar, Gupta, Pawan, Gardner, Linda, Ranganathan, David, Slavik, Roger, Dahlbom, Magnus, Herrmann, Ken, Delpassand, Ebrahim, Fendler, Wolfgang P, and Czernin, Johannes
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Clinical Trials and Supportive Activities ,Prostate Cancer ,Radiation Oncology ,Cancer ,Urologic Diseases ,6.1 Pharmaceuticals ,Good Health and Well Being ,Humans ,Male ,Prostatic Neoplasms ,Castration-Resistant ,Aged ,Lutetium ,Heterocyclic Compounds ,1-Ring ,Prospective Studies ,Middle Aged ,Treatment Outcome ,Neoplasm Metastasis ,Dipeptides ,Glutamate Carboxypeptidase II ,Radioisotopes ,Antigens ,Surface ,Aged ,80 and over ,Prostate-Specific Antigen ,Cohort Studies ,Molecular Targeted Therapy ,metastatic castration-resistant prostate cancer ,radionuclide therapy ,molecular radiotherapy ,prostate-specific membrane antigen ,Lu-177 ,RESIST-PC ,prospective randomized phase 2 trial ,theranostics ,177Lu ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
The objective of this study was to determine prospectively the efficacy profile of 2 activity regimens of 177Lu-PSMA therapy in patients with progressive metastatic castrate-resistant prostate cancer (mCRPC): 6.0 vs. 7.4 GBq. Methods: RESIST-PC (NCT03042312) was a prospective multicenter phase 2 trial. Patients with progressive mCRPC after ≥ 1 novel androgen-axis drug, either chemotherapy naïve or postchemotherapy, with sufficient bone marrow reserve, normal kidney function, and sufficient PSMA expression by PSMA PET were eligible. Patients were randomized (1:1) into 2 activity groups (6.0 or 7.4 GBq) and received up to 4 cycles every 8 wk. The primary endpoint was the efficacy of 177Lu-PSMA measured by the prostate-specific antigen (PSA) response rate (RR) after 2 cycles (≥50% decline from baseline). Secondary endpoints included the PSA RR (≥50% decline) at any time (best response), and overall survival (OS). Results: The study was closed at enrollment of 71/200 planned patients because of sponsorship transfer. We report here the efficacy of the University of California Los Angeles cohort results only (n = 43). The PSA RRs after 2 cycles and at any time were 11/40 (28%, 95% CI 15-44), 6/13 (46%, 95% CI 19-75), and 5/27 (19%, 95% CI 6-38), and 16/43 (37%, 95% CI 23-53), 7/14 (50%, 95% CI 23-77), and 9/29 (31%, 95% CI 15-51) in the whole cohort, the 6.0-GBq group, and the 7.4-GBq group, respectively (P = 0.12 and P = 0.31). The median OS was 14.0 mo (95% CI 10.1-17.9), 15.8 (95% CI 11.8-19.4), and 13.5 (95% CI 10.0-17.0) in the whole cohort, the 6.0-GBq group, and the 7.4 GBq group, respectively (P = 0.87). OS was longer in patients who experienced a PSA decline ≥ 50% at any time than in those who did not: median, 20.8 versus 10.8 mo (P = 0.005). Conclusion: In this prospective phase 2 trial of 177Lu-PSMA for mCRPC, the median OS was 14 mo. Despite the heterogeneous study population and the premature study termination, the efficacy profile of 177Lu-PSMA appeared to be favorable and comparable with both activity regimens (6.0 vs. 7.4 GBq). Results justify confirmation with real-world data matched-pair analysis and further clinical trials to refine and optimize the 177Lu-PSMA therapy administration scheme to improve tumor radiation dose delivery and efficacy.
- Published
- 2021
9. The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study
- Author
-
Armstrong, Wesley R, Gafita, Andrei, Zhu, Shaojun, Thin, Pan, Nguyen, Kathleen, Alano, Rejah, Lira, Stephanie, Booker, Kiara, Gardner, Linda, Grogan, Tristan, Elashoff, David, Allen-Auerbach, Martin, Dahlbom, Magnus, Czernin, Johannes, and Calais, Jeremie
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Digestive Diseases ,Cancer ,Clinical Research ,Dental/Oral and Craniofacial Disease ,Prostate Cancer ,Urologic Diseases ,Biomedical Imaging ,Aged ,Gallium Isotopes ,Gallium Radioisotopes ,Humans ,Male ,Middle Aged ,Positron Emission Tomography Computed Tomography ,Prostatic Neoplasms ,Tissue Distribution ,monosodium glutamate ,PSMA ,PET/CT ,xerostomia ,salivary glands ,salivary glands ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
The prostate-specific membrane antigen (PSMA) has been targeted for PET imaging and radioligand therapy (RLT) in patients with prostate cancer. Xerostomia is a common side effect of RLT because of the high salivary gland uptake of PSMA radioligands. Here, we aimed to determine the impact of monosodium glutamate (MSG) administration on PSMA-radioligand biodistribution within healthy organs and tumor lesions by using 68Ga-PSMA-11 PET imaging. Methods: Sixteen men with prostate cancer were randomized (1:1) into oral ingestion and oral topical application ("swishing") arms. Each subject underwent 2 68Ga-PSMA-11 PET/CT scans within 14 d under baseline and MSG conditions. The salivary glands and whole-body tumor lesions were segmented using qPSMA software. We quantified tracer uptake via SUVmean and SUVmax and compared parameters within each patient. Results: For the oral ingestion arm, salivary gland SUVmean and SUVmax decreased on average from the control scan to the MSG scan by 45% ± 15% (P = 0.004) and 53% ± 11% (P < 0.001), respectively. Tumor lesion SUVmean and SUVmax also decreased by 38% (interquartile range, -67% to -33%) and -52% (interquartile range, -70% to -49%), respectively (P = 0.018). Swishing had no significant effect on 68Ga-PSMA-11 accumulation in normal organs or tumor lesions. Conclusion: Oral ingestion but not topical application of MSG reduced 68Ga-PSMA-11 uptake in salivary glands. Tumor uptake also declined; therefore, the clinical application of MSG is unlikely to be useful in the framework of RLT.
- Published
- 2021
10. [18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial
- Author
-
Polverari, Giulia, Ceci, Francesco, Passera, Roberto, Crane, Jacquelyn, Du, Lin, Li, Gang, Fanti, Stefano, Bernthal, Nicholas, Eilber, Fritz C, Allen-Auerbach, Martin, Czernin, Johannes, Calais, Jeremie, and Federman, Noah
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Trials and Supportive Activities ,Rare Diseases ,Pediatric ,Pediatric Research Initiative ,Pediatric Cancer ,Prevention ,Biomedical Imaging ,Clinical Research ,Cancer ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,[F-18]FDG ,PET ,CT ,Sarcoma ,Neoadjuvant chemotherapy ,Therapy response ,Pediatrics ,PET/CT ,[18F]FDG ,Medical Biochemistry and Metabolomics ,Clinical sciences ,Oncology and carcinogenesis - Abstract
IntroductionThis is a prospective, single-center trial in pediatric patients with sarcoma aiming to evaluate [18F]FDG PET/CT as a tool for early response assessment to neoadjuvant chemotherapy (neo-CTX).MethodsBone or soft tissue sarcoma patients with (1) baseline [18F]FDG PET/CT within 4 weeks prior to the start of neo-CTX (PET1), (2) early interim [18F]FDG PET/CT (6 weeks after the start of neo-CTX (PET2), (3) evaluation of neo-CTX response by histology or MRI, and (4) definitive therapy after neo-CTX (surgery or radiation) were included. Semiquantitative PET parameters (SUVmax, SUVmean, SUVpeak, MTV and TLG) and their changes from PET1 to PET2 (ΔPET) were obtained. The primary endpoint was to evaluate the predictive value of PET1, PET2 and ΔPET parameters for overall survival (OS) and time to progression (TTP). The secondary outcome was to evaluate if [18F]FDG PET/CT can predict the response to neo-CTX assessed by histopathology or MRI. Primary and secondary outcomes were also evaluated in a subpopulation of patients with bone involvement only.ResultsThirty-four consecutive patients were enrolled (10 females; 24 males; median age 15.1 years). 17/34 patients (50%) had osteosarcoma, 13/34 (38%) Ewing's sarcoma, 2/34 (6%) synovial sarcoma and 2/34 (6%) embryonal liver sarcoma. Median follow-up was 39 months (range 16-84). Eight of 34 patients (24%) died, 9/34 (27%) were alive with disease, and 17/34 (50%) had no evidence of residual/recurrent disease. Fifteen of 34 (44%) and 19/34 (56%) were responders and non-responders, respectively. PET2-parameters were associated with longer TTP (p
- Published
- 2020
11. A randomized phase 2 trial in progress of flexible and extended dosing of 177Lu-PSMA-617 molecular radioligand therapy in mCRPC (FLEX-MRT).
- Author
-
Holzgreve, Adrien, primary, Delker, Astrid, additional, Ells, Zachary, additional, Brosch-Lenz, Julia, additional, Zhu, Shaojun, additional, Lira, Stephanie, additional, Nikitas, John, additional, Grogan, Tristan, additional, Elashoff, David, additional, Unterrainer, Lena M., additional, Dahlbom, Magnus, additional, Allen-Auerbach, Martin S., additional, Czernin, Johannes, additional, and Calais, Jeremie, additional
- Published
- 2024
- Full Text
- View/download PDF
12. Efficacy and toxicity of [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer in a real-world setting: Results from the U.S. Expanded Access Program and comparisons with phase 3 VISION data.
- Author
-
Calais, Jeremie, primary, Murthy, Vishnu, additional, Voter, Andrew, additional, Nguyen, Kathleen, additional, Allen-Auerbach, Martin S., additional, Caputo, Sydney, additional, Ledet, Elisa M., additional, Akerele, Opeoluwa, additional, Moradi Tuchayi, Abuzar, additional, Lawhn Heath, Courtney, additional, Carducci, Michael Anthony, additional, Pomper, Martin, additional, Paller, Channing Judith, additional, Czernin, Johannes, additional, Solnes, Lilja, additional, Hope, Thomas A., additional, Sartor, Oliver, additional, and Gafita, Andrei, additional
- Published
- 2024
- Full Text
- View/download PDF
13. Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers.
- Author
-
Farolfi, Andrea, Armstrong, Wesley R., Djaileb, Loic, Gafita, Andrei, Masatoshi Hotta, Allen-Auerbach, Martin, Unterrainer, Lena M., Fendler, Wolfgang P., Rettig, Matthew, Eiber, Matthias, Hofman, Michael S., Hadaschik, Boris, Herrmann, Ken, Czernin, Johannes, Calais, Jeremie, and Benz, Matthias R.
- Published
- 2024
- Full Text
- View/download PDF
14. Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence
- Author
-
Calais, Jeremie, Fendler, Wolfgang P, Eiber, Matthias, Gartmann, Jeannine, Chu, Fang-I, Nickols, Nicholas G, Reiter, Robert E, Rettig, Matthew B, Marks, Leonard S, Ahlering, Thomas E, Huynh, Linda M, Slavik, Roger, Gupta, Pawan, Quon, Andrew, Allen-Auerbach, Martin S, Czernin, Johannes, and Herrmann, Ken
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Urologic Diseases ,Aging ,Prostate Cancer ,Biomedical Imaging ,Aged ,Edetic Acid ,Gallium Isotopes ,Gallium Radioisotopes ,Humans ,Male ,Oligopeptides ,Positron Emission Tomography Computed Tomography ,Prostatic Neoplasms ,Recurrence ,prostate cancer ,biochemical recurrence ,PET/CT ,Ga-68-PSMA ,impact on implemented management ,68Ga-PSMA ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
In this prospective survey of referring physicians, we investigated whether and how 68Ga-labeled prostate-specific membrane antigen 11 (68Ga-PSMA-11) PET/CT affects the implemented management of prostate cancer patients with biochemical recurrence (BCR). Methods: We conducted a prospective survey of physicians (NCT02940262) who referred 161 patients with prostate cancer BCR (median prostate-specific antigen value, 1.7 ng/mL; range, 0.05-202 ng/mL). Referring physicians completed one questionnaire before the scan to indicate the treatment plan without 68Ga-PSMA-11 PET/CT information (Q1; n = 101), one immediately after the scan to denote intended management changes (Q2; n = 101), and one 3-6 mo later to document the final implemented management (Q3; n = 56). The implemented management was also obtained via electronic chart review or patient contact (n = 45). Results: A complete documented management strategy (Q1 + Q2 + implemented management) was available for 101 of 161 patients (63%). Seventy-six of these (75%) had a positive 68Ga-PSMA-11 PET/CT result. The implemented management differed from the prescan intended management (Q1) in 54 of 101 patients (53%). The postscan intended management (Q2) differed from the prescan intended management (Q1) in 62 of 101 patients (61%); however, these intended changes were not implemented in 29 of 62 patients (47%). Pelvic nodal and extrapelvic metastatic disease on 68Ga-PSMA-11 PET/CT (PSMA T0N1M0 and PSMA T0N1M1 patterns) was significantly associated with implemented management changes (P = 0.001 and 0.05). Conclusion: Information from 68Ga-PSMA-11 PET/CT brings about management changes in more than 50% of prostate cancer patients with BCR (54/101; 53%). However, intended management changes early after 68Ga-PSMA-11 PET/CT frequently differ from implemented management changes.
- Published
- 2018
15. Quantitative bone scan lesion area as an early surrogate outcome measure indicative of overall survival in metastatic prostate cancer
- Author
-
Brown, Matthew S, Kim, Grace Hyun J, Chu, Gregory H, Ramakrishna, Bharath, Allen-Auerbach, Martin, Fischer, Cheryce P, Levine, Benjamin, Gupta, Pawan K, Schiepers, Christiaan W, and Goldin, Jonathan G
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Aging ,Clinical Research ,Prostate Cancer ,Urologic Diseases ,Cancer ,Clinical Trials and Supportive Activities ,4.1 Discovery and preclinical testing of markers and technologies ,Evaluation of treatments and therapeutic interventions ,Detection ,screening and diagnosis ,6.1 Pharmaceuticals ,prostate cancer ,bone scan ,computer-aided diagnosis ,Clinical sciences ,Biomedical engineering - Abstract
A clinical validation of the bone scan lesion area (BSLA) as a quantitative imaging biomarker was performed in metastatic castration-resistant prostate cancer (mCRPC). BSLA was computed from whole-body bone scintigraphy at baseline and week 12 posttreatment in a cohort of 198 mCRPC subjects (127 treated and 71 placebo) from a clinical trial involving a different drug from the initial biomarker development. BSLA computation involved automated image normalization, lesion segmentation, and summation of the total area of segmented lesions on bone scan AP and PA views as a measure of tumor burden. As a predictive biomarker, treated subjects with baseline BSLA [Formula: see text] had longer survival than those with higher BSLA ([Formula: see text] and [Formula: see text]). As a surrogate outcome biomarker, subjects were categorized as progressive disease (PD) if the BSLA increased by a prespecified 30% or more from baseline to week 12 and non-PD otherwise. Overall survival rates between PD and non-PD groups were statistically different ([Formula: see text] and [Formula: see text]). Subjects without PD at week 12 had longer survival than subjects with PD: median 398 days versus 280 days. BSLA has now been demonstrated to be an early surrogate outcome for overall survival in different prostate cancer drug treatments.
- Published
- 2018
16. Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented
- Author
-
Calais, Jeremie, Czernin, Johannes, Eiber, Matthias, Fendler, Wolfgang P, Gartmann, Jeannine, Heaney, Anthony P, Hendifar, Andrew E, Pisegna, Joseph R, Hecht, J Randolph, Wolin, Edward M, Slavik, Roger, Gupta, Pawan, Quon, Andrew, Schiepers, Christiaan, Allen-Auerbach, Martin S, and Herrmann, Ken
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Cancer ,Biomedical Imaging ,Clinical Trials and Supportive Activities ,Aged ,Case Management ,Drugs ,Investigational ,Female ,Humans ,Image Processing ,Computer-Assisted ,Investigational New Drug Application ,Male ,Middle Aged ,Neuroendocrine Tumors ,Organometallic Compounds ,Positron Emission Tomography Computed Tomography ,Positron-Emission Tomography ,Prospective Studies ,Radiopharmaceuticals ,Receptors ,Somatostatin ,Surveys and Questionnaires ,neuroendocrine tumors ,somatostatin receptor ,PET/CT ,DOTATATE ,impact on implemented management ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
In this prospective referring-physician-based survey, we investigated the definite clinical impact of 68Ga-DOTATATE PET/CT on managing patients with neuroendocrine tumors (NETs). Methods: We prospectively studied 130 patients with 68Ga-DOTATATE PET/CT referred for initial or subsequent management decisions (NCT02174679). Referring physicians completed one questionnaire before the scan (Q1) to indicate the treatment plan without PET/CT information, one immediately after review of the imaging report to denote intended management changes (Q2), and one 6 mo later (Q3) to verify whether intended changes were in fact implemented. To further validate the Q3 responses, a systematic electronic chart review was conducted. Results: All 3 questionnaires were completed by referring physicians for 96 of 130 patients (74%). 68Ga-DOTATATE PET/CT resulted in intended management changes (Q2) in 48 of 96 patients (50%). These changes were finally implemented (Q3) in 36 of 48 patients (75%). Q3 responses were confirmed in all patients with an available electronic chart (36/96; 38%). Conclusion: This prospective study confirmed a significant impact of 68Ga-DOTATATE PET/CT on the intended management of patients with NETs (50% of changes) and notably demonstrated a high implementation rate (75%) of these intended management changes.
- Published
- 2017
17. Malignant Pheochromocytoma Presenting as a Large Adrenal Mass With Cavoatrial Tumor Thrombus
- Author
-
Yu, Run, primary, Allen-Auerbach, Martin S., additional, and Yeh, Michael W., additional
- Published
- 2024
- Full Text
- View/download PDF
18. Human Biodistribution and Radiation Dosimetry of 18F-Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway
- Author
-
Barrio, Martin J, Spick, Claudio, Radu, Caius G, Lassmann, Michael, Eberlein, Uta, Allen-Auerbach, Martin, Schiepers, Christiaan, Slavik, Roger, Czernin, Johannes, and Herrmann, Ken
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Biomedical Imaging ,Urologic Diseases ,Digestive Diseases ,Cancer ,Liver Disease ,Clinical Research ,Bioengineering ,5.1 Pharmaceuticals ,4.1 Discovery and preclinical testing of markers and technologies ,Generic health relevance ,Absorption ,Radiation ,Adenine Nucleotides ,Aged ,Arabinonucleosides ,Clofarabine ,Deoxycytidine Kinase ,Deoxyribonucleosides ,Female ,Fluorine Radioisotopes ,Humans ,Male ,Metabolic Clearance Rate ,Middle Aged ,Molecular Imaging ,Organ Specificity ,Positron-Emission Tomography ,Radiation Dosage ,Radiopharmaceuticals ,Signal Transduction ,Tissue Distribution ,Whole-Body Counting ,PET ,dosimetry ,clofarabine ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
18F-clofarabine, a nucleotide purine analog, is a substrate for deoxycytidine kinase (dCK), a key enzyme in the deoxyribonucleoside salvage pathway. 18F-clofarabine might be used to measure dCK expression and thus serve as a predictive biomarker for tumor responses to dCK-dependent prodrugs or small-molecule dCK inhibitors, respectively. As a prerequisite for clinical translation, we determined the human whole-body and organ dosimetry of 18F-clofarabine. Methods: Five healthy volunteers were injected intravenously with 232.4 ± 1.5 MBq of 18F-clofarabine. Immediately after tracer injection, a dynamic scan of the entire chest was acquired for 30 min. This was followed by 3 static whole-body scans at 45, 90, and 135 min after tracer injection. Regions of interest were drawn around multiple organs on the CT scan and copied to the PET scans. Organ activity was determined and absorbed dose was estimated with OLINDA/EXM software. Results: The urinary bladder (critical organ), liver, kidney, and spleen exhibited the highest uptake. For an activity of 250 MBq, the absorbed doses in the bladder, liver, kidney, and spleen were 58.5, 6.6, 6.3, and 4.3 mGy, respectively. The average effective dose coefficient was 5.1 mSv. Conclusion: Our results hint that 18F-clofarabine can be used safely in humans to measure tissue dCK expression. Future studies will determine whether 18F-clofarabine may serve as a predictive biomarker for responses to dCK-dependent prodrugs or small-molecule dCK inhibitors.
- Published
- 2017
19. 68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients
- Author
-
Fendler, Wolfgang Peter, Barrio, Martin, Spick, Claudio, Allen-Auerbach, Martin, Ambrosini, Valentina, Benz, Matthias, Bluemel, Christina, Grewal, Ravinder Kaur, Lapa, Constantin, Miederer, Matthias, Nicolas, Guillaume, Schuster, Tibor, Czernin, Johannes, and Herrmann, Ken
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Biomedical Imaging ,Cancer ,Clinical Research ,Clinical Trials and Supportive Activities ,Bioengineering ,Digestive Diseases ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Adult ,Aged ,False Positive Reactions ,Female ,Humans ,Image Enhancement ,Male ,Middle Aged ,Neuroendocrine Tumors ,Observer Variation ,Organometallic Compounds ,Positron Emission Tomography Computed Tomography ,Prospective Studies ,Radiopharmaceuticals ,Reproducibility of Results ,Sensitivity and Specificity ,neuroendocrine tumor ,agreement ,reproducibility ,PET/CT ,DOTATATE ,interobserver ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
We evaluated observer agreement for 68Ga-DOTATATE PET/CT interpretations in patients with neuroendocrine tumor (NET).Methods68Ga-DOTATATE PET/CT was performed on 50 patients with known or suspected NET of the small bowel (n = 19), pancreas (n = 14), lung (n = 4), or other location (n = 13). The images were reviewed by 7 observers, who used a standardized interpretation approach. The observers were classified as having a low level of experience (
- Published
- 2017
20. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma
- Author
-
Keu, Khun Visith, Witney, Timothy H, Yaghoubi, Shahriar, Rosenberg, Jarrett, Kurien, Anita, Magnusson, Rachel, Williams, John, Habte, Frezghi, Wagner, Jamie R, Forman, Stephen, Brown, Christine, Allen-Auerbach, Martin, Czernin, Johannes, Tang, Winson, Jensen, Michael C, Badie, Behnam, and Gambhir, Sanjiv S
- Subjects
Biomedical Imaging ,Gene Therapy ,Brain Cancer ,Cancer ,Immunization ,Vaccine Related ,Genetics ,Biotechnology ,Orphan Drug ,Bioengineering ,Brain Disorders ,Rare Diseases ,Development of treatments and therapeutic interventions ,5.2 Cellular and gene therapies ,Aged ,Brain Neoplasms ,Female ,Gene Expression ,Genes ,Reporter ,Genetic Therapy ,Glioma ,Humans ,Immunotherapy ,Interleukin-13 ,Male ,Middle Aged ,Neoplasm Recurrence ,Local ,Positron-Emission Tomography ,Prospective Studies ,Receptors ,Antigen ,T-Cell ,T-Lymphocytes ,Cytotoxic ,Thymidine Kinase ,Biological Sciences ,Medical and Health Sciences - Abstract
High-grade gliomas are aggressive cancers that often become rapidly fatal. Immunotherapy using CD8+ cytotoxic T lymphocytes (CTLs), engineered to express both herpes simplex virus type 1 thymidine kinase (HSV1-TK) and interleukin-13 (IL-13) zetakine chimeric antigen receptor (CAR), is a treatment strategy with considerable potential. To optimize this and related immunotherapies, it would be helpful to monitor CTL viability and trafficking to glioma cells. We show that noninvasive positron emission tomography (PET) imaging with 9-[4-[18F]fluoro-3-(hydroxymethyl)butyl]guanine ([18F]FHBG) can track HSV1-tk reporter gene expression present in CAR-engineered CTLs. [18F]FHBG imaging was safe and enabled the longitudinal imaging of T cells stably transfected with a PET reporter gene in patients. Further optimization of this imaging approach for monitoring in vivo cell trafficking should greatly benefit various cell-based therapies for cancer.
- Published
- 2017
21. The incidence of thyroid cancer in focal hypermetabolic thyroid lesions
- Author
-
Barrio, Martin, Czernin, Johannes, Yeh, Michael W, Diaz, Miguel F Palma, Gupta, Pawan, Allen-Auerbach, Martin, Schiepers, Christiaan, and Herrmann, Ken
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Biomedical Imaging ,Clinical Research ,Rare Diseases ,Adult ,Aged ,Aged ,80 and over ,Female ,Fluorine Radioisotopes ,Fluorodeoxyglucose F18 ,Humans ,Incidence ,Incidental Findings ,Male ,Middle Aged ,Positron Emission Tomography Computed Tomography ,Radiopharmaceuticals ,Retrospective Studies ,Thyroid Gland ,Thyroid Neoplasms ,Young Adult ,fluorine-18 fluorodeoxyglucose ,incidental findings ,PET ,thyroid ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
BackgroundThe clinical significance of incidental thyroid abnormalities discovered in fluorine-18 fluorodeoxyglucose (F-FDG) PET/computed tomography (CT) (FDG PET/CT) studies remains controversial. The aim of this large retrospective study was to (a) determine the prevalence of focal F-FDG thyroid uptake on whole-body F-FDG PET/CT studies carried out for nonthyroid cancers and (b) to test whether intense focal F-FDG thyroid uptake is associated with malignancy.Materials and methodsA total of 11 921 F-FDG PET/CT studies in 6216 patients carried out at our institution between January 2012 and December 2014 were analyzed. We retrospectively reviewed the medical records of these patients. Eight hundred and forty-five/6216 (13.6%) patients had a thyroid incidentaloma on the basis of the clinical F-FDG PET/CT report. One hundred and sixty/845 (18.9%) of these underwent ultrasound and 98 (61.3%) of these underwent a fine-needle aspiration (FNA). Twenty-six of these 98 (26.5%) patients underwent thyroidectomy. Thyroid lesion and background standardized uptake value (SUVs) for each patient were measured upon review of the F-FDG PET/CT study. We measured maximum standardized uptake value (SUVmax), thyroid to background TL/TBG, thyroid to bloodpool TL/BP and thyroid to liver TL/L ratios in benign and malignant lesions. Receiver operating curves were calculated to determine optimal cut-off values between malignant and benign lesions.ResultsTwenty-one of the 98 patients who underwent FNA biopsy or thyroidectomy had malignant disease (21.4%). Malignant lesions had significantly higher thyroid lesion SUVmax, TL/TBG, TL/BP, and TL/L than benign nodules. The receiver operating curves derived cut-off ratio TL/TBG of more than 2.0 differentiated benign from malignant lesions best with a specificity and sensitivity of 0.76 and 0.88, respectively.ConclusionThe incidence of malignancy in biopsied focal hypermetabolic thyroid lesions is 21.4%. Lesions on F-FDG PET/CT studies, with a ratio TL/TBG more than 2.0, warrant further work-up with ultrasound and FNA to exclude malignancy.
- Published
- 2016
22. Differences and Common Ground in177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers
- Author
-
Farolfi, Andrea, primary, Armstrong, Wesley R., additional, Djaileb, Loic, additional, Gafita, Andrei, additional, Hotta, Masatoshi, additional, Allen-Auerbach, Martin, additional, Unterrainer, Lena M., additional, Fendler, Wolfgang P., additional, Rettig, Matthew, additional, Eiber, Matthias, additional, Hofman, Michael S., additional, Hadaschik, Boris, additional, Herrmann, Ken, additional, Czernin, Johannes, additional, Calais, Jeremie, additional, and Benz, Matthias R., additional
- Published
- 2024
- Full Text
- View/download PDF
23. PSMA PET/CT Dual-Time-Point Imaging: Nice to Have or Need to Have?
- Author
-
Unterrainer, Lena M., primary, Ruchalski, Kathleen, additional, Allen-Auerbach, Martin S., additional, Calais, Jeremie, additional, and Benz, Matthias R., additional
- Published
- 2024
- Full Text
- View/download PDF
24. Transforming an Academic Radiochemistry Facility for Positron Emission Tomography Drug cGMP Compliance
- Author
-
Zhu, Shaojun, Mosessian, Sherly, Kroeger, Kurt, Sadeghi, Saman, Slavik, Roger, Kinloch, Simon, Moore, Melissa, Allen-Auerbach, Martin, Czernin, Johannes, and Phelps, Michael
- Published
- 2020
- Full Text
- View/download PDF
25. Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
- Author
-
Herrmann, Ken, Czernin, Johannes, Wolin, Edward M, Gupta, Pawan, Barrio, Martin, Gutierrez, Antonio, Schiepers, Christiaan, Mosessian, Sherly, Phelps, Michael E, and Allen-Auerbach, Martin S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Biomedical Imaging ,Cancer ,Neurosciences ,Adult ,Aged ,Aged ,80 and over ,Female ,Humans ,Image Interpretation ,Computer-Assisted ,Male ,Middle Aged ,Multimodal Imaging ,Neoplasm Metastasis ,Neuroendocrine Tumors ,Organometallic Compounds ,Physicians ,Positron-Emission Tomography ,Referral and Consultation ,Research Report ,Surveys and Questionnaires ,Tomography ,X-Ray Computed ,NET ,neuroendocrine tumors ,somatostatin receptor ,PET ,DOTATATE ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
UnlabelledSomatostatin receptor imaging with (68)Ga-DOTATATE PET/CT (DOTATATE) is increasingly used for managing patients with neuroendocrine tumors. The objective of this study was to determine referring physicians' perspectives on the impact of DOTATATE on the management of neuroendocrine tumors.MethodsA set of 2 questionnaires (pre-PET and post-PET) was sent to the referring physicians of 100 consecutive patients with known or suspected neuroendocrine tumors, who were evaluated with DOTATATE. Questionnaires on 88 patients were returned (response rate, 88%). Referring physicians categorized the DOTATATE findings on the basis of the written PET reports as negative, positive, or equivocal for disease. The likelihood for metastatic disease was scored as low, moderate, or high. The intended management before and changes as a consequence of the PET study were indicated.ResultsThe indications for PET/CT were initial and subsequent treatment strategy assessments in 14% and 86% of patients, respectively. Referring physicians reported that DOTATATE led to a change in suspicion for metastatic disease in 21 patients (24%; increased and decreased suspicion in 9 [10%] and 12 [14%] patients, respectively). Intended management changes were reported in 53 of 88 (60%) patients. Twenty patients (23%) scheduled to undergo chemotherapy were switched to treatments without chemotherapy, and 6 (7%) were switched from watch-and-wait to other treatment strategies. Conversely, 5 patients (6%) were switched from their initial treatment strategy to watch-and-wait.ConclusionThis survey of referring physicians demonstrates a substantial impact of DOTATATE on the intended management of patients with neuroendocrine tumors.
- Published
- 2015
26. High 68 Ga-FAPI-46 uptake in a pulmonary necrotizing granuloma in a patient with subcutaneous lipoma
- Author
-
Hotta, Masatoshi, Benz, Matthias R., Allen-Auerbach, Martin S., Crompton, Joseph G., Roth, Michael D., Eilber, Fritz C., and Calais, Jeremie
- Published
- 2022
- Full Text
- View/download PDF
27. Perceived Misinterpretation Rates in Oncologic 18F-FDG PET/CT Studies: A Survey of Referring Physicians
- Author
-
Karantanis, Dimitrios, Kalkanis, Dimitrios, Czernin, Johannes, Herrmann, Ken, Pomykala, Kelsey L, Bogsrud, Trond V, Subramaniam, Rathan M, Lowe, Val J, and Allen-Auerbach, Martin S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Biomedical Imaging ,Clinical Trials and Supportive Activities ,Clinical Research ,Cancer ,Diagnostic Errors ,Fluorodeoxyglucose F18 ,Health Care Surveys ,Humans ,Internet ,Medical Oncology ,Multimodal Imaging ,Neoplasms ,Positron-Emission Tomography ,Radiopharmaceuticals ,Referral and Consultation ,Surveys and Questionnaires ,overinterpretation ,false-positive results ,false-negative results ,accuracy ,pitfall ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
UnlabelledBecause only pathologic examination can confirm the presence or absence of malignant disease in cancer patients, a certain rate of misinterpretation in any kind of imaging study is inevitable. For the accuracy of interpretation to be improved, determination of the nature, causes, and magnitude of this problem is needed. This study was designed to collect pertinent information from physicians referring patients for oncologic (18)F-FDG PET/CT.MethodsA total of 662 referring physicians completed an 11-question survey focused on their experience with the interpretation of oncologic (18)F-FDG PET/CT studies. The participants were oncologists (36.1%; n = 239), hematologists (14.5%; n = 96), radiation oncologists (7.4%; n = 49), surgeons (33.8%; n = 224), and other physicians (8.2%; n = 54). Questions were aimed at determining the frequency, nature, and causes of scan misinterpretations as well as potential solutions to reduce the frequency of misinterpretations.ResultsPerceived misinterpretation rates ranged from 5% to 20%, according to most (59.3%) of the participants; 20.8% of respondents reported rates of less than 5%. Overinterpretation rather than underinterpretation was more frequently encountered (68.9% vs. 8.7%, respectively). Limited availability of a patient's history and limited experience of interpreters were the major contributors to this phenomenon, according to 46.8% and 26.7% of the participants, respectively. The actions most commonly suggested to reduce misinterpretation rates (multiple suggestions were possible) were the institution of multidisciplinary meetings (59.8%), the provision of adequate history when ordering an examination (37.4%), and a discussion with imaging specialists when receiving the results of the examination (38.4%).ConclusionOverinterpretation rather than underinterpretation of oncologic (18)F-FDG PET/CT studies prevails in clinical practice, according to referring physicians. Closer collaboration of imaging specialists with referring physicians through more multidisciplinary meetings, improved communication, and targeted training of interpreting physicians are actions suggested to reduce the rates of misinterpretation of oncologic (18)F-FDG PET/CT studies.
- Published
- 2014
28. Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters
- Author
-
Wieder, Hinrich A, Lassmann, Michael, Allen-Auerbach, Martin S, Czernin, Johannes, and Herrmann, Ken
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Aging ,Clinical Trials and Supportive Activities ,Urologic Diseases ,Cancer ,Pain Research ,Clinical Research ,Prostate Cancer ,Chronic Pain ,Radium ,Bone targeted radiopharmaceuticals ,Alpha emitters - Abstract
Various single or multi-modality therapeutic options are available to treat pain of bone metastasis in patients with prostate cancer. Different radionuclides that emit β-rays such as (153)Samarium and (89)Strontium and achieve palliation are commercially available. In contrast to β-emitters, (223)Radium as a α-emitter has a short path-length. The advantage of the α-emitter is thus a highly localized biological effect that is caused by radiation induced DNA double-strand breaks and subsequent cell killing and/or limited effectiveness of cellular repair mechanisms. Due to the limited range of the α-particles the bone surface to red bone marrow dose ratio is also lower for (223)Radium which is expressed in a lower myelotoxicity. The α emitter (223)Radium dichloride is the first radiopharmaceutical that significantly prolongs life in castrate resistant prostate cancer patients with wide-spread bone metastatic disease. In a phase III, randomized, double-blind, placebo-controlled study 921 patients with castration-resistant prostate cancer and bone metastases were randomly assigned. The analysis confirmed the (223)Radium survival benefit compared to the placebo (median, 14.9 mo vs 11.3 mo; P < 0.001). In addition, the treatment results in pain palliation and thus, improved quality of life and a delay of skeletal related events. At the same time the toxicity profile of (223)Radium was favourable. Since May 2013, (223)Radium dichloride (Xofigo(®)) is approved by the US Food and Drug Administration.
- Published
- 2014
29. Visual and whole-body quantitative analyses of 68 Ga-DOTATATE PET/CT for prognosis of outcome after PRRT with 177Lu-DOTATATE.
- Author
-
Hotta, Masatoshi, Sonni, Ida, Thin, Pan, Nguyen, Kathleen, Gardner, Linda, Ciuca, Liliana, Hayrapetian, Artineh, Lewis, Meredith, Lubin, David, and Allen-Auerbach, Martin
- Abstract
Background: Somatostatin receptors (SSTR) represent an ideal target for nuclear theranostics applications in neuroendocrine tumors (NET). Studies suggest that high uptake on SSTR-PET is associated with response to SSTR peptide receptor radionuclide therapy (PRRT). The purpose of this study was to evaluate the role of baseline whole-body (WB)
68 Ga-DOTATATE PET/CT (SSTR-PET) quantitative parameters, and the presence of NET lesions without uptake on SSTR-PET, as outcome prognosticator in patients with NET treated with PRRT. Methods: Patients with NET who underwent at least 4177 Lu-DOTATATE PRRT cycles between 07/2016 and 03/2021 were included in this retrospective analysis if they fulfilled the following inclusion criteria: SSTR-PET within 6 months of 1st PRRT cycle, follow-up CT and/or MRI performed > 6 months after the 4th cycle of PRRT. The SSTR-PET analysis consisted of a visual and a quantitative analysis done independently by two board-certified physicians. The visual analysis assessed the presence of NET lesions visible on the SSTR-PET co-registered CT. The quantitative analysis consisted in contouring all SSTR-avid lesions on SSTR-PET and extracting WB quantitative parameters: SUVmean (WB-SUVmean), SUVmax of the lesion with highest uptake (H-SUVmax), and tumor volume (WB-TV). WB-SSTR-PET parameters and the presence of SSTR-PET-negative lesions were correlated to radiologic response (assessed by RECIST 1.1 criteria) and progression-free survival (PFS). Fisher's exact test, Mann–Whitney's U test and Kaplan–Meier curves with Cox-regression analysis were used for the statistical analysis. Results: Forty patients (F/M: 21/19; 34/40 with gastro-entero-pancreatic (GEP) NET, 6/40 with non-GEP NET) were included in the analysis. The median follow-up period after the 4th PRRT cycle was 25.7 months (range 15.2–59.1). Fourteen/40 (35%) patients showed radiologic response (RECIST PR). PFS event was observed in 17/40 (42.5%) patients. Thirteen/40 (32.5%) patients had SSTR-PET-negative lesions at baseline. Higher WB-SUVmean and H-SUVmax were associated with better response (p = 0.015 and 0.005, respectively). The presence of SSTR-PET-negative lesions and lower WB-SUVmean were associated with shorter PFS (p = 0.026 and 0.008, respectively). Conclusion: Visual and quantitative analyses of baseline SSTR-PET can yield valuable information to prognosticate outcomes after177 Lu-DOTATATE PRRT. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
30. Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers
- Author
-
Hope, Thomas A., primary, Benz, Matthias, additional, Jiang, Fei, additional, Thompson, Daniel, additional, Barbato, Francesco, additional, Juarez, Roxana, additional, Hernandez Pampaloni, Miguel, additional, Allen-Auerbach, Martin, additional, Gupta, Pawan, additional, Fendler, Wolfgang P., additional, and Calais, Jeremie, additional
- Published
- 2023
- Full Text
- View/download PDF
31. PET/CT in Oncology: Current Status and Perspectives
- Author
-
Czernin, Johannes, Allen-Auerbach, Martin, Nathanson, David, and Herrmann, Ken
- Subjects
Physical Sciences ,Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Bioengineering ,Biomedical Imaging ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Initial treatment strategies ,Molecular imaging ,Oncology ,PET/CT ,Subsequent treatment strategies - Abstract
The discovery of the Warburg effect in the early twentieth century followed by the development of the fluorinated glucose analogue 18F-fluorodeoxyglucose (18F-FDG) and the invention of positron emission tomographs laid the foundation of clinical PET/CT. This review discusses the challenges and obstacles in clinical adoption of this technique. We then discuss advances in instrumentation, including the critically important introduction of PET/CT and current PET/CT protocols. Moreover, we provide evidence for the clinical utility of PET/CT for patient management and its potential impact on patient outcome, and address its cost and cost-effectiveness. Although this review largely focuses on 18F-FDG imaging, we also discuss a variety of additional molecular imaging approaches that can be used for cancer phenotyping with PET. Throughout this review we emphasize the critical contributions of CT to the strength of PET/CT.
- Published
- 2013
32. FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas.
- Author
-
Benz, Matthias R, Czernin, Johannes, Tap, William D, Eckardt, Jeffrey J, Seeger, Leanne L, Allen-Auerbach, Martin S, Dry, Sarah M, Phelps, Michael E, Weber, Wolfgang A, and Eilber, Fritz C
- Subjects
Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
Purpose. The aim of this study was to prospectively evaluate whether FDG-PET allows an accurate assessment of histopathologic response to neoadjuvant treatment in adult patients with primary bone sarcomas. Methods. Twelve consecutive patients with resectable, primary high grade bone sarcomas were enrolled prospectively. FDG-PET/CT imaging was performed prior to the initiation and after completion of neoadjuvant treatment. Imaging findings were correlated with histopathologic response. Results. Histopathologic responders showed significantly more pronounced decreases in tumor FDG-SUVmax from baseline to late follow up than non-responders (64 +/- 19% versus 29 +/- 30 %, resp.; P = .03). Using a 60% decrease in tumor FDG-uptake as a threshold for metabolic response correctly classified 3 of 4 histopathologic responders and 7 of 8 histopathologic non-responders as metabolic responders and non-responders, respectively (sensitivity, 75%; specificity, 88%). Conclusion. These results suggest that changes in FDG-SUVmax at the end of neoadjuvant treatment can identify histopathologic responders and non-responders in adult primary bone sarcoma patients.
- Published
- 2010
33. Comparison of CT, PET, and PET/CT for Staging of Patients with Indolent Non-Hodgkin’s Lymphoma
- Author
-
Fueger, Barbara J., Yeom, Kristen, Czernin, Johannes, Sayre, James W., Phelps, Michael E., and Allen-Auerbach, Martin S.
- Subjects
Medicine & Public Health ,Imaging / Radiology ,PET ,PET/CT ,Indolent lymphoma - Abstract
The aim was to investigate the potential impact of positron emission tomography (PET)/computed tomography (CT) as compared to PET and CT on the staging of patients with indolent lymphoma.PET/CTs from 45 patients with indolent lymphoma undergoing staging or restaging were studied. Clinical follow-up, additional imaging, and histology served as the gold standard.PET/CT correctly diagnosed 92 nodal regions as positive for lymphomatous involvement and 458 as disease free vs 68 and 449 for PET and 64 and 459 for CT, respectively. The respective sensitivities, specificities, and accuracies were 99%, 100%, and 99.8% for PET/CT, 68%, 97.5%, and 92.2% for PET, and 70%, 100%, and 94.7% for CT. PET/CT performed significantly better than PET (p
- Published
- 2009
34. 68Ga-FAPI-46 PET/CT Tracer Uptake in CT-diagnosed Intra-Abdominal Fat Necrosis
- Author
-
Maliha, Peter George, primary, Allen-Auerbach, Martin, additional, Hotta, Masatoshi, additional, and Calais, Jeremie, additional
- Published
- 2023
- Full Text
- View/download PDF
35. 68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study
- Author
-
Mei, Riccardo, primary, Kessler, Lukas, additional, Pabst, Kim M., additional, Weber, Manuel, additional, Schmidkonz, Christian, additional, Rischpler, Christoph, additional, Zacho, Helle Damgaard, additional, Hope, Thomas, additional, Schwarzenböck, Sarah M., additional, Allen-Auerbach, Martin, additional, Emmett, Louise, additional, Ferdinandus, Justin, additional, Unterrainer, Marcus, additional, Schaarschmidt, Benedikt M., additional, Umutlu, Lale, additional, Farolfi, Andrea, additional, Castellucci, Paolo, additional, Nanni, Cristina, additional, Telo, Silvi, additional, Fanti, Stefano, additional, Herrmann, Ken, additional, and Fendler, Wolfgang P., additional
- Published
- 2023
- Full Text
- View/download PDF
36. Nuclear Medicine Approaches to Treatment of Neuroendocrine Tumors
- Author
-
Herrmann, Ken, Werner, Rudolf A., Blümel, Christina, Allen-Auerbach, Martin S., and Pisegna, Joseph R., editor
- Published
- 2015
- Full Text
- View/download PDF
37. Abstract CT023: Phase 1 trial of CD19/CD20 bispecific chimeric antigen receptor-engineered naïve/memory T cells for relapsed or refractory non-Hodgkin lymphoma
- Author
-
Puliafito, Benjamin R., primary, Walthers, Christopher, additional, Ji, Brenda, additional, Ghafouri, Sanaz N., additional, Naparstek, Jacob, additional, Trent, Jacqueline, additional, Chen, Jia M., additional, Roshandell, Mobina, additional, Harris, Caitlin, additional, Khericha, Mobina, additional, Schweppe, Thomas, additional, Berent-Maoz, Beata, additional, Gosliner, Stanley B., additional, Almaktari, Amr, additional, Ceja, Melanie Ayala, additional, Allen-Auerbach, Martin S., additional, Said, Jonathan, additional, Nawaly, Karla, additional, Mead, Monica, additional, de Vos, Sven, additional, Young, Patricia A., additional, Oliai, Caspian, additional, Schiller, Gary J., additional, Timmerman, John M., additional, Ribas, Antoni, additional, Chen, Yvonne Y., additional, and Larson, Sarah M., additional
- Published
- 2023
- Full Text
- View/download PDF
38. Data from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- Author
-
Larson, Sarah M., primary, Walthers, Christopher M., primary, Ji, Brenda, primary, Ghafouri, Sanaz N., primary, Naparstek, Jacob, primary, Trent, Jacqueline, primary, Chen, Jia Ming, primary, Roshandell, Mobina, primary, Harris, Caitlin, primary, Khericha, Mobina, primary, Schweppe, Thomas, primary, Berent-Maoz, Beata, primary, Gosliner, Stanley B., primary, Almaktari, Amr, primary, Ceja, Melanie Ayala, primary, Allen-Auerbach, Martin S., primary, Said, Jonathan, primary, Nawaly, Karla, primary, Mead, Monica, primary, de Vos, Sven, primary, Young, Patricia A., primary, Oliai, Caspian, primary, Schiller, Gary J., primary, Timmerman, John M., primary, Ribas, Antoni, primary, and Chen, Yvonne Y., primary
- Published
- 2023
- Full Text
- View/download PDF
39. Figure S5 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- Author
-
Larson, Sarah M., primary, Walthers, Christopher M., primary, Ji, Brenda, primary, Ghafouri, Sanaz N., primary, Naparstek, Jacob, primary, Trent, Jacqueline, primary, Chen, Jia Ming, primary, Roshandell, Mobina, primary, Harris, Caitlin, primary, Khericha, Mobina, primary, Schweppe, Thomas, primary, Berent-Maoz, Beata, primary, Gosliner, Stanley B., primary, Almaktari, Amr, primary, Ceja, Melanie Ayala, primary, Allen-Auerbach, Martin S., primary, Said, Jonathan, primary, Nawaly, Karla, primary, Mead, Monica, primary, de Vos, Sven, primary, Young, Patricia A., primary, Oliai, Caspian, primary, Schiller, Gary J., primary, Timmerman, John M., primary, Ribas, Antoni, primary, and Chen, Yvonne Y., primary
- Published
- 2023
- Full Text
- View/download PDF
40. Table S1 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- Author
-
Larson, Sarah M., primary, Walthers, Christopher M., primary, Ji, Brenda, primary, Ghafouri, Sanaz N., primary, Naparstek, Jacob, primary, Trent, Jacqueline, primary, Chen, Jia Ming, primary, Roshandell, Mobina, primary, Harris, Caitlin, primary, Khericha, Mobina, primary, Schweppe, Thomas, primary, Berent-Maoz, Beata, primary, Gosliner, Stanley B., primary, Almaktari, Amr, primary, Ceja, Melanie Ayala, primary, Allen-Auerbach, Martin S., primary, Said, Jonathan, primary, Nawaly, Karla, primary, Mead, Monica, primary, de Vos, Sven, primary, Young, Patricia A., primary, Oliai, Caspian, primary, Schiller, Gary J., primary, Timmerman, John M., primary, Ribas, Antoni, primary, and Chen, Yvonne Y., primary
- Published
- 2023
- Full Text
- View/download PDF
41. SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors
- Author
-
Hope, Thomas A., primary, Allen-Auerbach, Martin, additional, Bodei, Lisa, additional, Calais, Jeremie, additional, Dahlbom, Magnus, additional, Dunnwald, Lisa K., additional, Graham, Michael M., additional, Jacene, Heather A., additional, Heath, Courtney Lawhn, additional, Mittra, Erik S., additional, Wright, Chadwick L., additional, Fendler, Wolfgang P., additional, Herrmann, Ken, additional, Taïeb, David, additional, and Kjaer, Andreas, additional
- Published
- 2023
- Full Text
- View/download PDF
42. SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET:Imaging Neuroendocrine Tumors
- Author
-
Hope, Thomas A., Allen-Auerbach, Martin, Bodei, Lisa, Calais, Jeremie, Dahlbom, Magnus, Dunnwald, Lisa K., Graham, Michael M., Jacene, Heather A., Heath, Courtney Lawhn, Mittra, Erik S., Wright, Chadwick L., Fendler, Wolfgang P., Herrmann, Ken, Taïeb, David, Kjaer, Andreas, Hope, Thomas A., Allen-Auerbach, Martin, Bodei, Lisa, Calais, Jeremie, Dahlbom, Magnus, Dunnwald, Lisa K., Graham, Michael M., Jacene, Heather A., Heath, Courtney Lawhn, Mittra, Erik S., Wright, Chadwick L., Fendler, Wolfgang P., Herrmann, Ken, Taïeb, David, and Kjaer, Andreas
- Published
- 2023
43. CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- Author
-
Larson, Sarah M., primary, Walthers, Christopher M., additional, Ji, Brenda, additional, Ghafouri, Sanaz N., additional, Naparstek, Jacob, additional, Trent, Jacqueline, additional, Chen, Jia Ming, additional, Roshandell, Mobina, additional, Harris, Caitlin, additional, Khericha, Mobina, additional, Schweppe, Thomas, additional, Berent-Maoz, Beata, additional, Gosliner, Stanley B., additional, Almaktari, Amr, additional, Ceja, Melanie Ayala, additional, Allen-Auerbach, Martin S., additional, Said, Jonathan, additional, Nawaly, Karla, additional, Mead, Monica, additional, de Vos, Sven, additional, Young, Patricia A., additional, Oliai, Caspian, additional, Schiller, Gary J., additional, Timmerman, John M., additional, Ribas, Antoni, additional, and Chen, Yvonne Y., additional
- Published
- 2022
- Full Text
- View/download PDF
44. Clinical applications of PET/CT and SPECT/CT imaging
- Author
-
Czernin, Johannes, primary, Israel, Ora, additional, Herrmann, Ken, additional, Barrio, Martin, additional, Nathanson, David, additional, and Allen-Auerbach, Martin, additional
- Published
- 2017
- Full Text
- View/download PDF
45. 68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study.
- Author
-
Mei, Riccardo, Kessler, Lukas, Pabst, Kim M., Weber, Manuel, Schmidkonz, Christian, Rischpler, Christoph, Zacho, Helle Damgaard, Hope, Thomas, Schwarzenbock, Sarah M., Allen-Auerbach, Martin, Emmett, Louise, Ferdinandus, Justin, Unterrainer, Marcus, Schaarschmidt, Benedikt M., Umutlu, Lale, Farolfi, Andrea, Castellucci, Paolo, Nanni, Cristina, Telo, Silvi, and Fanti, Stefano
- Published
- 2023
- Full Text
- View/download PDF
46. PET/CT Imaging in Breast Cancer, Gastrointestinal Cancers, Gynecological Cancers and Lymphoma
- Author
-
Allen-Auerbach, Martin, Czernin, Johannes, Schiepers, Christiaan, Baert, A. L., editor, Sartor, K., editor, and Schiepers, Christiaan, editor
- Published
- 2006
- Full Text
- View/download PDF
47. 68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs
- Author
-
Werner, Rudolf A., Bluemel, Christina, Allen-Auerbach, Martin S., Higuchi, Takahiro, and Herrmann, Ken
- Published
- 2015
- Full Text
- View/download PDF
48. Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips
- Author
-
Sun, Na, primary, Yang, Yingying, additional, Miao, Hui, additional, Redublo, Peter, additional, Liu, Hongtao, additional, Liu, Wenfei, additional, Huang, Yen-Wen, additional, Teng, Pai-Chi, additional, Zhang, Ceng, additional, Zhang, Ryan Y., additional, Smalley, Matthew, additional, Yang, Peng, additional, Chou, Shih-Jie, additional, Huai, Kevin, additional, Zhang, Zhicheng, additional, Lee, Yi-Te, additional, Wang, Jasmine J., additional, Wang, Jing, additional, Liang, Icy Y., additional, Zhang, Tiffany X., additional, Zhang, Dongyun, additional, Liang, Li, additional, Weiss, Paul S., additional, Posadas, Edwin M., additional, Donahue, Timothy, additional, Hecht, J. Randolph, additional, Allen-Auerbach, Martin S., additional, Bergsland, Emily K., additional, Hope, Thomas A., additional, Pei, Renjun, additional, Zhu, Yazhen, additional, Tseng, Hsian-Rong, additional, and Heaney, Anthony P., additional
- Published
- 2022
- Full Text
- View/download PDF
49. Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
- Author
-
Lapa, Constantin, Werner, Rudolf A, Bluemel, Christina, Lueckerath, Katharina, Muegge, Dirk O, Strate, Alexander, Haenscheid, Heribert, Schirbel, Andreas, Allen-Auerbach, Martin S, Bundschuh, Ralph A, Buck, Andreas K, and Herrmann, Ken
- Published
- 2014
- Full Text
- View/download PDF
50. Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial
- Author
-
Sonni, Ida, primary, Felker, Ely R., additional, Lenis, Andrew T., additional, Sisk, Anthony E., additional, Bahri, Shadfar, additional, Allen-Auerbach, Martin, additional, Armstrong, Wesley R., additional, Suvannarerg, Voraparee, additional, Tubtawee, Teeravut, additional, Grogan, Tristan, additional, Elashoff, David, additional, Eiber, Matthias, additional, Raman, Steven S., additional, Czernin, Johannes, additional, Reiter, Robert E., additional, and Calais, Jeremie, additional
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.